文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

大分割立体定向放疗联合全脑放疗治疗脑转移瘤患者的回顾性研究

Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases.
PubMed 文献 · Radiat Oncol · 2022-07-26

该回顾性研究纳入2018年5月至2020年7月50例脑转移瘤患者(111个病灶),接受HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)。颅内客观缓解率(RECIST 1.1)为62.1%,(RANO-BM)为58.6%;颅内局部控制率为93.1%,6个月和12个月iLC率分别为90.8%和57.4%。中位总生存期13.6个月,未观察到3级及以上急性毒性。

要点

  • HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)治疗脑转移瘤,颅内局部控制率93.1%。
  • 中位生存期13.6个月,KPS≥70患者为16.5个月,未观察到3级及以上急性毒性。
  • 多因素分析显示性别、KPS评分和 gross tumor volume 是生存的显著影响因素。

核心结论

  • HFSRT联合WBRT是脑转移瘤患者安全有效的局部治疗方式。

研究设计与样本

  • 回顾性研究,纳入2018年5月至2020年7月50例脑转移瘤患者(111个病灶),接受HFSRT(18 Gy/3F)联合WBRT(40 Gy/20F)。

主要发现

  • RECIST 1.1和RANO-BM标准评估的颅内客观缓解率分别为62.1%和58.6%。
  • 颅内局部控制率为93.1%,6个月和12个月iLC率分别为90.8%和57.4%。
  • 中位颅内无进展生存期未达到(范围0-23个月)。
  • 6、12、24个月总生存率分别为74.2%、58.2%和22.9%;KPS≥70患者分别为83.8%、70.5%和29.7%。
  • 全部患者和KPS≥70患者的中位生存时间分别为13.6个月和16.5个月。

关键数值与推荐

  • 单因素分析中KPS评分对生存有统计学意义。
  • 多因素分析中性别、KPS评分和gross tumor volume是生存的显著因素。
  • 总生存与RPA、SIR、BS-BM和GGS分级显著相关。
  • 未观察到3级及以上急性毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To evaluate the clinical outcomes of hypofractionated stereotactic radiotherapy (HFSRT) combined with whole brain radiotherapy (WBRT) in patients with brain metastases (BMs). MATERIALS AND METHODS: From May 2018 to July 2020, 50 patients (111 lesions) received HFSRT (18 Gy/3F) + WBRT (40 Gy/20F). The RECIST 1.1 and RANO-BM criteria were used to evaluate treatment efficacy. Five prognostic indexes (RPA, GPA, SIR, BS-BM, and GGS) were applied. The primary endpoint was intracranial local control (iLC). Secondary endpoints were overall survival (OS) and the safety of treatment. RESULTS: Intracranial objective response rates (iORR) using the RECIST 1.1 and RANO-BM criteria were 62.1% and 58.6%, respectively. The iLC rate was 93.1%, the 6- and 12-month iLC rates were 90.8% and 57.4%, respectively. The median intracranial progression-free survival (iPFS) was not reached (range 0-23 months). The 6-, 12-, and 24-month OS rates were 74.2%, 58.2%, and 22.9%, respectively. The KPS score showed statistical significance in univariate analysis of survival. The 6, 12, and 24 month OS rates for patients with KPS ≥ 70 were 83.8%, 70.5%, and 29.7%, respectively. The median survival time (MST) for all patients and for patients with KPS ≥ 70 were 13.6 and 16.5 months, respectively. Sex, KPS score, and gross tumor volume were significant factors in the multivariate analysis of survival. OS was significantly associated with RPA, SIR, BS-BM, and GGS classes. No acute toxicities of grade 3 or higher were noted. CONCLUSION: HFSRT combined with WBRT is a safe and effective local treatment modality for BM patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xie XY, Peng HH, Zhang X, et al. Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases. Radiat Oncol. 2022. PMID: 35883147. doi:10.1186/s13014-022-02096-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。